Table 1.
Characteristics of patients in the original study population and in the propensity score matched (PSM) sample used for the present analysis.
| Original population N = 1188 | Vaccinated N = 581 | Unvaccinated N = 607 | PSM sample population N = 1004 | Vaccinated N = 502 | Unvaccinated N = 502 | |
|---|---|---|---|---|---|---|
| AGE (median, IQR, range) | 69 (61–76), (20–93) | 72 (64–77), (30–90) | 66 (58–73), (20–93) | 70 (62–76), (30–93) | 71 (63–77), (30–90) | 69 (62–75), (33–93) |
| Gender | ||||||
| M | 831 (69.9) | 429 (73.8) | 402 (66.2) | 713 (71.0) | 357 (71.1) | 356 (70.9) |
| F | 357 (30.1) | 152 (26.2) | 205 (33.8) | 291 (29.0) | 145 (28.9) | 146 (29.1) |
| ECOG PS | ||||||
| 0 | 686 (57.7) | 312 (53.7) | 374 (61.6) | 580 | 287 | 293 |
| 1 | 431 (36.3) | 235 (40.4) | 196 (32.3) | 358 | 183 | 175 |
| 2 | 53 (4.5) | 22 (3.8) | 31 (5.1) | 52 | 22 | 30 |
| 3 | 3 (0.3) | 2 (0.3) | 1 (0.2) | 0 | 0 | 0 |
| Unknown | 15 (1.3) | 10 (1.7) | 5 (0.8) | 14 | 10 | 4 |
| Primary tumour | ||||||
| Lung | 645 (54.3) | 337 (58.0) | 308 (50.7) | 580 (55.8) | 282 (56.2) | 278 (55.4) |
| RCC | 201 (16.9) | 107 (18.4) | 94 (15.5) | 168 (16.7) | 94 (18.7) | 74 (14.7) |
| Melanoma | 153 (12.9) | 52 (9.0) | 101 (16.6) | 119 (11.9) | 45 (9.0) | 74 (14.7) |
| UC | 64 (5.4) | 29 (5.0) | 35 (5.8) | 57 (5.7) | 28 (5.6) | 29 (5.8) |
| H&N | 41 (3.5) | 14 (2.4) | 27 (4.4) | 33 (3.3) | 13 (2.6) | 20 (4.0) |
| Other | 84 (7.1) | 42 (7.2) | 42 (6.9) | 67 (6.7) | 40 (8.0) | 27 (5.4) |
| ICI treatment line | ||||||
| 1 | 663 (55.8) | 316 (54.4) | 347 (57.2) | 552 (55.0) | 273 (54.4) | 279 (55.6) |
| 2 | 426 (35.9) | 214 (36.8) | 212 (34.9) | 369 (36.7) | 186 (37.0) | 183 (36.5) |
| 3 | 96 (8.0) | 48 (8.3) | 48 (7.9) | 81 (8.1) | 41 (8.2) | 40 (8.0) |
| Unknown | 3 (0.3) | 3 (0.5) | 0 | 2 (0.2) | 2 (0.4) | 0 |
| Splenectomy | ||||||
| Yes | 8 (0.7) | 5 (0.9) | 3 (0.5) | 8 (0.8) | 5 (1.0) | 3 (0.6) |
| No | 915 (77.0) | 455 (78.3) | 460 (75.8) | 776 (77.3) | 385 (76.7) | 391 (77.9) |
| Unknown | 265 (22.3) | 121 (20.8) | 144 (23.7) | 220 (21.9) | 112 (22.3) | 108 (21.5) |
| Therapy | ||||||
| ICI/ICI + ICI | 1075 (90.5) | 527 (90.7) | 548 (90.3) | 917 (91.3) | 454 (90.4) | 463 (92.2) |
| ICI + Other∗ | 113 (9.5) | 54 (9.3) | 59 (9.7) | 87 (8.7) | 48 (9.6) | 39 (7.8) |
| Immunotherapy type | ||||||
| Single agent (ICI) | 1122 (94.4) | 546 (94.0) | 576 (94.9) | 949 (94.5) | 470 (93.6) | 479 (95.4) |
| Combinations (ICI + ICI) | 66 (5.6) | 35 (6.0) | 31 (5.1) | 55 (5.5) | 32 (6.4) | 26 (5.2) |
| Comorbidity | ||||||
| Yes | 875 (73.7) | 467 (86.4) | 408 (67.2) | 772 (76.9) | 390 (77.7) | 382 (76.1) |
| No | 313 (26.3) | 114 (19.6) | 199 (32.8) | 232 (23.1) | 112 (22.3) | 120 (23.9) |
| Comorbidity type | ||||||
| Cardiovascular | 202 (17.0) | 118 (20.3) | 84 (13.8) | 177 (17.6) | 96 (19.1) | 81 (16.1) |
| Asthma/COPD | 401 (33.8) | 225 (38.7) | 176 (29.0) | 351 (35.0) | 185 (36.9) | 166 (33.1) |
| Diabetes | 185 (15.6) | 98 (16.9) | 87 (14.3) | 162 (16.1) | 80 (15.9) | 82 (16.3) |
| Others | 283 (23.8) | 143 (24.6) | 140 (23.1) | 253 (25.2) | 123 (24.5) | 130 (25.9) |
| Smoking habits | ||||||
| Current | 287 (24.2) | 125 (21.5) | 207 (34.1) | 243 (24.2) | 105 (20.9) | 138 (27.5) |
| Former | 512 (43.1) | 288 (49.6) | 224 (36.9) | 441 (43.9) | 243 (48.4) | 198 (39.4) |
| Never | 358 (30.1) | 151 (26.0) | 162 (26.7) | 293 (29.2) | 139 (27.7) | 154 (30.7) |
| Unknown | 31 (2.6) | 17 (2.9) | 14 (2.3) | 27 (2.7) | 15 (3.0) | 12 (2.4) |
IQR = interquartile range; ECOG PS = European Cooperative Oncology Group Performance Status; RCC = renal cell carcinoma; UC = urothelial cancer; H&N = head and neck carcinoma; ICI = immune checkpoint inhibitor; COPD = chronic obstructive pulmonary disease.